Compare PHVS & ALG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHVS | ALG |
|---|---|---|
| Founded | 2015 | 1955 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2020 | 1996 |
| Metric | PHVS | ALG |
|---|---|---|
| Price | $33.56 | $169.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 3 |
| Target Price | $41.82 | ★ $225.00 |
| AVG Volume (30 Days) | ★ 331.1K | 148.2K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.81% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.41 |
| Revenue | N/A | ★ $1,603,715,000.00 |
| Revenue This Year | N/A | $5.26 |
| Revenue Next Year | N/A | $3.97 |
| P/E Ratio | ★ N/A | $69.73 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.72 | $145.76 |
| 52 Week High | $35.33 | $233.29 |
| Indicator | PHVS | ALG |
|---|---|---|
| Relative Strength Index (RSI) | 61.64 | 66.90 |
| Support Level | $24.73 | $167.49 |
| Resistance Level | N/A | $174.81 |
| Average True Range (ATR) | 1.61 | 5.32 |
| MACD | 0.17 | 2.17 |
| Stochastic Oscillator | 64.53 | 82.50 |
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use. Its products include agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck-mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, snow removal equipment, etc. The company's reportable segments are Vegetation Management, which generates the maximum revenue, and Industrial Equipment. Geographically, the company generates maximum revenue from the United States, followed by Canada, France, the UK, Brazil, the Netherlands, and other regions.